

DIRECTOR AND EXECUTIVE OFFICER COMPENSATION

The following table is a summary of compensation (excluding compensation securities) paid, awarded to or earned by the executive officers and directors for the fiscal years ended December 31, 2021 and 2020:

Name and Position	Year	Salary, Consulting Fee, Retainer of Commission (\$)	Bonus (\$)	Committee or Meeting Fees (\$)	Value of Perquisites ⁽¹⁾ (\$)	Value of All Other Compensation (\$)	Total Compensation (\$)
Steven McAuley ⁽²⁾ <i>President, CEO, Interim CFO, Chairman and Director</i>	2021	552,000	Nil	Nil	Nil	Nil	552,000
	2020	191,156	Nil	Nil	Nil	19,525	210,681
Jennifer Archibald ⁽³⁾ <i>Former CFO</i>	2021	7,500	Nil	Nil	Nil	Nil	7,500
	2020	N/A	N/A	N/A	N/A	N/A	N/A
Kyle Appleby ⁽⁴⁾ <i>Former CFO</i>	2021	21,000	Nil	Nil	Nil	Nil	21,000
	2020	9,000	Nil	Nil	Nil	Nil	9,000
Tenzin Khangsar ⁽⁵⁾ <i>Chief Business Officer</i>	2021	161,882	Nil	Nil	Nil	Nil	161,882
	2020	11,550	Nil	Nil	Nil	Nil	11,550
Andrejs Bunkse ⁽⁶⁾ <i>Director</i>	2021	37,605	Nil	Nil	Nil	Nil	37,605
	2020	10,061	Nil	Nil	Nil	Nil	10,061
Yoshi Tyler ⁽⁷⁾ <i>Director</i>	2021	219,811	Nil	Nil	Nil	Nil	219,811
	2020	N/A	N/A	N/A	N/A	N/A	N/A
Dustin Klein ⁽⁸⁾ <i>Former Director and SVP, Business Development</i>	2021	20,892	Nil	Nil	Nil	Nil	20,892
	2020	67,073	Nil	Nil	Nil	Nil	67,073

(1) "Perquisites" include perquisites provided to an executive officer or director that are not generally available to all employees and that, in aggregate, are: (a) \$15,000, if the executive officer or director's total salary for the financial year is \$150,000 or less; (b) 10% of the executive officer or director's salary for the financial year if the executive officer or director's total salary for the financial year is greater than \$150,000 but less than \$500,000; or (c) \$50,000 if the executive officer or director's total salary for the financial year is \$500,000 or greater.

(2) Mr. McAuley was appointed as CEO and as a director on January 4, 2019. Mr. McAuley was appointed interim CFO upon the resignation of Jennifer Archibald as CFO on July 22, 2022.

(3) Ms. Archibald was appointed as CFO on December 22, 2021 and resigned as CFO on July 22, 2022.

(4) Mr. Appleby was appointed as CFO on September 28, 2020 and resigned as CFO on December 22, 2021. All compensation payable in connection with the provision of Mr. Appleby's services as CFO are paid to CFO Advantage Inc., a company controlled by Mr. Appleby.

(5) Mr. Khangsar was appointed as Chief Business Officer on September 1, 2021. Prior to that, he was working as a consultant contractor. Of the total compensation amount earned by Mr. Khangsar during the year 2021, \$81,882 was for consulting fees and the remaining \$80,000 was employment salary.

(6) Mr. Bunkse was appointed as a director on June 13, 2019. His annual compensation amounts in 2021 and 2020 were USD\$30,000 and USD\$7,500, respectively, which were converted to Canadian dollars for the purposes of the table above using the Bank of Canada average rates of 1.2535 and 1.3415, respectively.

(7) Ms. Tyler was appointed as a director on April 1, 2021 and Ms. Tyler was also the President of Kai Medical Laboratory, LLC, a wholly-owned subsidiary of the Company. Ms. Tyler is not standing for re-election as a director and accordingly, will cease to be a director on November 3, 2022.

(8) Mr. Klein was appointed as a director on April 30, 2019 and resigned as a director on March 1, 2021.

STOCK OPTIONS AND OTHER COMPENSATION SECURITIES

The following table sets out all Options, being the only compensation securities granted or issued by the Company to any director or NEO in the year ended December 31, 2021, for services provided or to be provided, directly or indirectly, to the Company or any subsidiary thereof. Each Option is exercisable into one Share.

Name and Position	Type of Compensation Security	Number of Compensation Securities and Percentage of Class	Date of Issue or Grant	Issue, Conversion or Exercise Price	Closing Price of Security or Underlying Security on Date of Grant ⁽¹⁾	Expiry Date
Steven McAuley ⁽²⁾ <i>President, CEO, Interim CFO, Chairman and Director</i>	Nil	Nil	Nil	Nil	Nil	Nil
Jennifer Archibald ⁽³⁾ <i>Former CFO</i>	Options	400,000 5.87% ⁽⁴⁾	December 22, 2021	\$0.24	\$0.265	December 22, 2026
Kyle Appleby <i>Former CFO</i>	Nil	Nil	Nil	Nil	Nil	Nil
Tenzin Khangsar <i>Chief Business Officer</i>	Options	750,000 11.01% ⁽⁴⁾	February 3, 2021	\$0.25	\$0.33	February 3, 2026
Andrejs Bunkse ⁽⁵⁾ <i>Director</i>	Options	500,000 7.34% ⁽⁴⁾	March 4, 2021	\$0.57	\$0.76	March 4, 2026
Yoshi Tyler ⁽⁶⁾ <i>Director</i>	Options	300,000 4.40% ⁽⁴⁾	May 7, 2021	\$0.57	\$0.59	May 7, 2026
Dustin Klein ⁽⁷⁾ <i>Former Director and SVP</i>	Nil	Nil	Nil	Nil	Nil	Nil

(1) All of the compensation securities granted or issued in 2021 were comprised of Options. The closing price per Share on the Canadian Securities Exchange (the "CSE") on December 31, 2021, being the last trading day of the Company's most recently completed fiscal year, was \$0.31.

(2) As at December 31, 2021, Mr. McAuley did not hold any Options but did hold 7,000,000 Shares that were granted to Mr. McAuley as a bonus in a prior fiscal year.

(3) As at December 31, 2021, Ms. Archibald held 400,000 Options, representing an equal number of underlying Shares with 25% vesting immediately, 25% after three months, 25% after six months, 25% after nine months.

(4) Represents the percentage of the issued and outstanding Options of the Company as at December 31, 2021.

(5) As at December 31, 2021, Mr. Bunkse held 1,100,000 Options, representing an equal number of underlying Shares, vesting immediately.

(6) As at December 31, 2021, Ms. Tyler held 1,075,000 Options, representing an equal number of underlying Shares, vesting immediately.

(7) As at December 31, 2021, Mr. Klein did not hold any Options.

EXERCISE OF COMPENSATION SECURITIES

The following table sets out all exercised compensation securities, being solely comprised of Options, during the Company's most recently completed fiscal year ended December 31, 2021.

Name and Position	Type of compensation security	Number of underlying securities exercised	Exercise price per security	Date of exercise	Closing price per security on date of exercise	Difference between exercise price and closing price on date of exercise	Total value on exercise date
Tenzin Khangsar <i>Chief Business Officer</i>	Options	125,000	\$0.06	March 17, 2021	\$0.91	\$0.85	\$113,750
		125,000	\$0.06	June 28, 2021	\$0.63	\$0.57	\$78,750

SECURITIES AUTHORIZED FOR THE ISSUANCE UNDER EQUITY COMPENSATION PLAN

The following table sets forth details regarding the Option Plan, being the Company's only equity compensation plan, as of December 31, 2021.

Plan Category	Number of shares to be issued upon exercise of outstanding Options	Weighted-average exercise price of outstanding options	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) ⁽¹⁾
Equity compensation plans approved by shareholders (Option Plan)	6,814,459	\$0.16	27,130,043
Equity compensation plans not approved by shareholders	N/A	N/A	N/A
Total	6,814,459	\$0.16	27,130,043

(1) Based on 339,445,021 Shares outstanding as at December 31, 2021. The Option Plan is a rolling plan under which the Company can grant such number of Options as is equal to 10% of the Company's issued and outstanding Shares from time to time.